Hyalocytes: Essential vitreous cells in vitreoretinal health and disease

Takeshi Kita; Taiji Sakamoto; Tatsuro Ishibashi

doi:10.1007/978-1-4939-1086-1_10

Hyalocytes: Essential vitreous cells in vitreoretinal health and disease

Takeshi Kita, Taiji Sakamoto, Tatsuro Ishibashi

研究成果: 書籍/レポートタイプへの寄稿 › 章

11 被引用数 (Scopus)

抄録

Vitreoretinal interface diseases are common causes of vision loss or metamorphopsia in spite of recent advances in clinical ophthalmology including vitreoretinal surgery, pharmacological therapy such as anti-VEGF agents, and gene-mediated therapy. The vitreous is often used as a therapeutic place or platform for these therapies; therefore, more detailed knowledge about the environment of the vitreous is required.

本文言語	英語
ホスト出版物のタイトル	Vitreous
ホスト出版物のサブタイトル	In Health and Disease
出版社	Springer New York
ページ	151-164
ページ数	14
ISBN（電子版）	9781493910861
ISBN（印刷版）	9781493910854
DOI	https://doi.org/10.1007/978-1-4939-1086-1_10
出版ステータス	出版済み - 1月 1 2014
外部発表	はい

!!!All Science Journal Classification (ASJC) codes

医学（全般）

文献へのアクセス

10.1007/978-1-4939-1086-1_10

他のファイルとリンク

引用スタイル

@inbook{9d9bb79fe1d64e419ddb5dba9d7c2b7f,

title = "Hyalocytes: Essential vitreous cells in vitreoretinal health and disease",

abstract = "Vitreoretinal interface diseases are common causes of vision loss or metamorphopsia in spite of recent advances in clinical ophthalmology including vitreoretinal surgery, pharmacological therapy such as anti-VEGF agents, and gene-mediated therapy. The vitreous is often used as a therapeutic place or platform for these therapies; therefore, more detailed knowledge about the environment of the vitreous is required.",

author = "Takeshi Kita and Taiji Sakamoto and Tatsuro Ishibashi",

year = "2014",

month = jan,

day = "1",

doi = "10.1007/978-1-4939-1086-1_10",

language = "English",

isbn = "9781493910854",

pages = "151--164",

booktitle = "Vitreous",

publisher = "Springer New York",

address = "United States",

}

TY - CHAP

T1 - Hyalocytes

T2 - Essential vitreous cells in vitreoretinal health and disease

AU - Kita, Takeshi

AU - Sakamoto, Taiji

AU - Ishibashi, Tatsuro

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Vitreoretinal interface diseases are common causes of vision loss or metamorphopsia in spite of recent advances in clinical ophthalmology including vitreoretinal surgery, pharmacological therapy such as anti-VEGF agents, and gene-mediated therapy. The vitreous is often used as a therapeutic place or platform for these therapies; therefore, more detailed knowledge about the environment of the vitreous is required.

AB - Vitreoretinal interface diseases are common causes of vision loss or metamorphopsia in spite of recent advances in clinical ophthalmology including vitreoretinal surgery, pharmacological therapy such as anti-VEGF agents, and gene-mediated therapy. The vitreous is often used as a therapeutic place or platform for these therapies; therefore, more detailed knowledge about the environment of the vitreous is required.

UR - http://www.scopus.com/inward/record.url?scp=84956824766&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956824766&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-1086-1_10

DO - 10.1007/978-1-4939-1086-1_10

M3 - Chapter

AN - SCOPUS:84956824766

SN - 9781493910854

SP - 151

EP - 164

BT - Vitreous

PB - Springer New York

ER -

Hyalocytes: Essential vitreous cells in vitreoretinal health and disease

抄録

!!!All Science Journal Classification (ASJC) codes

文献へのアクセス

他のファイルとリンク

フィンガープリント

引用スタイル